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Abstract
3-Nitrobenzanthrone (3-NBA) is a potent mutagen and suspected human carcinogen detected in
diesel exhaust particulate and ambient air pollution. It requires metabolic activation via
nitroreduction to promote DNA adduct formation and tumorigenesis. NAD(P)H:quinone
oxidoreductase 1 (NQO1) has been previously implicated as the major nitroreductase responsible
for 3-NBA activation, but it has recently been reported that human aldo-keto reductase 1C3
(AKR1C3) displays nitroreductase activity towards the chemotherapeutic agent PR-104A. We
sought to determine whether AKR1C isozymes could display nitroreductase activity towards other
nitrated compounds and bioactivate 3-NBA. Using discontinuous enzymatic assays monitored by
UV-HPLC, we determined that AKR1C1-1C3 catalyze three successive 2-electron nitroreductions
towards 3-NBA to form the reduced product, 3-aminobenzanthrone (3-ABA).  Evidence of the
nitroso- and hydroxylamino-intermediates were obtained by UPLC-HRMS. Km, kcat, and kcat/Km
values were determined for recombinant AKR1C and NQO1 and compared. We found that
AKR1C1, AKR1C3, and NQO1 have very similar apparent catalytic efficiencies (8 min-1 mM-1
vs. 7 min-1 mM-1) despite the higher kcat of NQO1 (0.058 min-1 vs. 0.012 min-1). AKR1C1-1C3
possess a much lower Km than NQO1 which suggests that they may be more important than NQO1
at the low concentrations of 3-NBA to which humans are exposed. Given that inhalation represents
the primary source of 3-NBA exposure, we chose to evaluate the relative importance of AKR1C1-
1C3 and NQO1 in human lung epithelial cell lines. Our data suggest that the combined activities
of AKR1C1-1C3 and NQO1 contribute equally to the reduction of 3-NBA in A549 and HBEC3-
KT cell lines and together represent approximately 50% of the intracellular nitroreductase activity
towards 3-NBA. These findings have significant implications for the metabolism of nitrated
polycyclic aromatic hydrocarbons and suggests that the hitherto unrecognized nitroreductase
activity of AKR1C enzymes should be further investigated.
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Introduction
Lung cancer is the leading cause of cancer death worldwide.1 Although lung cancer is largely
attributed to tobacco smoking,2-3 outdoor air pollution represents a growing threat to public
health.4-6 The World Health Organization (WHO) estimated 223,000 lung cancer deaths in 2010
were due to air pollution which has since been designated as a Group 1 “known human carcinogen”
by the International Agency for Research on Cancer (IARC).4, 7 A major source of air pollution
includes diesel engine exhaust which has also been classified as a Group 1 “known human
carcinogen” by IARC.8 Carcinogens found uniquely in diesel exhaust particulates include the
nitrated polycyclic aromatic hydrocarbons (NO2-PAHs) which may increase the risk of lung cancer
in exposed individuals.9-14 NO2-PAHs  are  adhered  to  superfine  particulate  matter  (PM2.5)  in
ambient air which can accumulate in the alveolar epithelia of the deep lung of exposed
individuals15-16 and have been detected in lung tissue of non-smokers with lung cancer.12, 17
However, not all individuals exposed to diesel exhaust develop lung cancer, indicating that gene-
environment interactions may be important in determining individual risk for developing this
disease.18-19 NO2-PAHs require metabolic activation to exert their mutagenic and tumorigenic
effects,20 and identification of human enzymes that can metabolically activate these carcinogens
will provide insight into identifying genetic variants and transcriptomic changes that may
determine individual susceptibility. We chose to further characterize the metabolic activation of
3-nitrobenzanthrone (3-nitro-7H-benz[de]anthracen-7-one, 3-NBA)21 since  it  is  the  most
mutagenic compound identified in the Ames test to date,22-23 and it is a potent mutagen and lung
carcinogen in rodents.24-28 Metabolic activation of 3-NBA involves a 6-electron reduction of the
nitro-group involving sequential formation of the nitroso-, hydroxylamino-, and amine products
catalyzed by cytosolic nitroreductases (Figure  1).29-31 The hydroxylamino intermediate, N-
hydroxy-3-aminobenzanthrone (N-OH-3-ABA) is intercepted by sulfonation or acetylation,
creating a good leaving group for attack of the intermediate nitrenium or carbenium ion to DNA
bases resulting in the formation of DNA adducts.32-36 Its final product, 3-aminobenzanthrone (3-
ABA, Figure 1) can also be activated by peroxidases to yield either a nitrenium or carbenium ion
that can contribute to DNA adduct formation.37-38 3-NBA exposure leads to DNA adduct formation
in vitro and in multiple organs in vivo in rodents34, 39-42 and in human cells.16, 43-46 3-ABA has been
found in the urine of salt-mine workers occupationally exposed to diesel exhaust which indicates
human exposure to 3-NBA and their ability to metabolize it.47
Figure 1. Proposed pathways of metabolic activation of 3-NBA and resulting DNA adduct
formation. See text for details. Abbreviations used: NQO1, NAD(P)H:quinone oxidoreductase 1;
NAT1/2, N,O-acetyltransferase isozymes; SULT1A1/1A2, sulfotransferases 1A1 and 1A2; P450,
cytochrome P450; MPO, myeloperoxidase. Modified from Arlt et al., 2006.37
Identification of genes involved in the metabolic activation of representative NO2-PAHs, such as
3-NBA, will be necessary to identify genotypes of sensitive individuals or predict phenotypic
changes that may sensitize individuals to diesel exhaust exposures. 3-NBA has previously been
shown to be metabolically activated by xanthine oxidase (XO), NADPH:cytochrome P450
oxidoreductase (POR), and NAD(P)H:quinone oxidoreductase 1 (NQO1) to yield N-OH-3-ABA
or 3-ABA.33, 48-50  Inhibition studies have shown that NQO1 is the primary enzyme that catalyzes
the nitroreduction of 3-NBA in liver in vitro.48, 51-52
Since human aldo-keto reductase 1C3 (AKR1C3) displays greater nitroreductase activity than
NQO1 towards the activation of the cancer chemotherapeutic agent PR-104A, we sought to
characterize whether AKRs could contribute to the nitroreduction of 3-NBA in humans.53 The
ability of AKR1Cs to display nitroreductase activity against PR-104A was unexpected since these
enzymes typically conduct a two electron reduction on carbonyl groups.54  AKR1C1-1C3 are
highly expressed in human lung tissue which is relevant as inhalation is the primary route of
exposure to NO2-PAHs.17, 55-56 We demonstrate here that human AKR1C1-1C3 are able to catalyze
the nitroreduction of 3-NBA and therefore may be involved in toxification of NO2-PAHs.
Materials and Methods
Caution: 3-NBA and its derivatives are potent mutagens and suspected carcinogens and should be
handled in accordance with NIH Guidelines for the Use of Chemical Carcinogens.
Chemicals and reagents
3-NBA, N-OH-3-ABA, and 3-ABA were synthesized as described previously.31, 57-58 The synthesis
of 3-NOBA was performed from 3-ABA following the experimental protocol reported by Fifer et
al. for the synthesis of similar nitroso-PAHs.59 The purity and identity of these compounds were
verified by UV spectroscopy, high resolution mass spectrometry, and high-field 1H NMR
spectroscopy. All other chemicals were of the highest grade available, and all solvents were of
HPLC  grade.  (S)-(+)-1,2,3,4-tetrahydro-1-naphthol (S-tetralol), flavin adenine dinucleotide
(FAD), dithiothreitol (DTT), 1-acenaphthenol, dicoumarol (Dic), allopurinol, rotenone, and D-
glucose-6-phosphate (G6P) were purchased from Millipore-Sigma (St. Louis, MO).  Nicotinamide
adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+) were
purchased from Roche Diagnostics (Indianapolis, IN). Glucose-6-phosphate dehydrogenase
(G6PD) was purchased from Worthington Biochemical Corporation (Lakewood, NJ).
Androsterone was purchased from Steraloids (Wilton, NH); 2,6-dichloroindophenol (DCPIP) and
salicylic acid were purchased from Acros Organics (Geel, Belgium). Flufenamic acid (FA),
ursodeoxycholate, and indomethacin were purchased from ICN Biomedicals, Inc. (Aurora, Ohio).
Discontinuous enzymatic assays
Human recombinant enzymes AKR1C1-AKR1C3 were prepared and purified as previously
described.60 Homogenous human recombinant NQO1 was purchased from Millipore Sigma (St.
Louis, MO). Enzymes were shown to be homogenous by SDS-PAGE analysis prior to use and
their specific activities were in accord with published values.61-62
In order to identify whether AKR1C1-1C3 catalyzed the nitroreduction of 3-NBA, enzymatic
assays were prepared in a cell-free system. Typical assays to determine catalytic efficiencies with
AKR1C1-1C3 contained 1 – 30 μM 3-NBA, 4% DMSO (v/v), and a NADPH regeneration system
to maintain 1 mM NADPH in 50 mM potassium phosphate buffer, pH 7.0. These reactions were
maintained at 37 °C in the dark with gentle agitation. The NADPH regeneration system consisted
of  1 mM G6P,  1 mM NADP+, and 2 units/mL G6PD. The reactions with AKR1C1-1C3 were
initiated with 0.5 μM enzyme. Typical reaction mixtures with NQO1 contained 1 – 30 μM 3-NBA,
1 μM FAD, 1 mM DTT, and a NADPH-regeneration system in 50 mM potassium phosphate
buffer, pH 7.0. Reactions were initiated with 0.25 μM enzyme and maintained in the dark at 37°C
with gentle agitation. The amount of enzyme used was always in the linear range for each protein
as determined by plots of initial velocity versus enzyme concentrations. In control reactions,
AKR1C1-1C3 or NQO1 was omitted from the mixtures. Reactions for each substrate concentration
were repeated 3 to 5 times.
To stop enzymatic reactions, aliquots were extracted twice with 1.5-fold volume of ice-cold ethyl
acetate saturated with H2O. Samples were vortexed vigorously for ³ 20 sec and centrifuged at
16,000 × g to help phase separation. The organic phase was then collected and dried under vacuum
with a SpeedVac concentrator (Thermo Fisher Scientific, San Jose, CA). The residue was re-
dissolved in methanol for analysis by UV-HPLC. 3-ABA was identified by its retention time and
UV spectra which were compared to authentic standards and quantified using calibration curves.
High resolution mass spectrometry confirmed analyte identity.  Amounts of 3-ABA (nmol) were
plotted against time and the initial velocity was estimated by the slope of the linear portion of the
progress curve in the first 5-10% of the reaction. Velocity vs. substrate concentration curves were
analyzed using GraphPad Prism Version 7 (GraphPad Software, La Jolla, CA) to calculate Vmax,
Km, and kcat.
UV-HPLC analysis
Data were acquired using a Waters Alliance 2695 HPLC system (Waters Corporation, Milford,
MA) coupled to a Waters Alliance 2996 Photodiode Array Detector (Waters Corporation, Milford,
MA). Separations were accomplished on a reverse-phase (RP) column (Zorbax-ODS C18, 5 μm,
4.6 mm × 250 mm) (Dupont Co., Wilmington, DE) with a guard column at ambient temperature.
The mobile phase consisted of 5 mM ammonium acetate and 0.1% trifluoroacetic acid (TFA) (v/v)
in H2O (solvent A) and 5 mM ammonium acetate and 0.1% TFA (v/v) in acetonitrile (solvent B)
and was delivered at a flow rate of 0.5 mL/min. The linear gradient elution program was as follows:
5% to 95% B over 30 min, followed by an isocratic hold at 95% B for another 10 min. At 40 min,
B was returned to 5% in 1 min and the column was equilibrated for 19 minutes before the next
injection. The total run time for each analysis was 60 min.
Liquid chromatography high resolution mass spectrometry (LC-HRMS)
For LC-HRMS analysis, enzymatic reactions were prepared as above: aliquots were extracted
twice with 1.5-fold volume of ice-cold ethyl acetate saturated with H2O and centrifuged at 16,000
× g to help phase separation. The organic phase was dried under vacuum with a SpeedVac
concentrator. The residue was re-dissolved in 50% methanol in water and cleaned up by passage
through a CoStar Spin-X HPLC 0.2 µm nylon filter (Corning Incorporated, Coning, NY). 5 μL
aliquots were analyzed on a Waters nano-Acquity Ultra Performance Liquid Chromatography
(UPLC) system (Waters Corporation, Milford, MA) coupled to a QE-HF mass spectrometer
(Thermo Fisher Scientific, San Jose, CA). Separations were accomplished on an analytical column
(C18, 1.7 µm BEH130, 150 µm × 100 mm) (Waters Corporation, Milford, MA) at 55 °C. The
mobile phase consisted of 0.1% formic acid (v/v) in H2O (solvent A) and 0.1% formic acid (v/v)
in acetonitrile (solvent B) and was delivered at a flow rate of 1.6 µL/min. The linear gradient
elution was as follows: an isocratic hold at 5% B for 5 min, 5% to 95 % B over 30 min, followed
by an isocratic hold at 95% B for another 10 min. At 46 min, B was returned to 5% in 2 min and
the column was equilibrated for 12 min before the next injection. The total run time for each
analysis was 60 min. The mass spectrometer was operated in the positive ion mode, with a Microm
source after system calibration with the manufacturer’s calibration mixture. The ionization voltage
was set to 1.5 kV and the capillary temperature was set to 200 °C. Full scan spectra were acquired
with a resolving power of 120,000 in a mass range from m/z 100 to 800. The Xcalibur software
version 2.0 (Thermo Fisher Scientific, San Jose, CA) was used to control the UPLC-MS/MS
system and to process data.
Cell Culture
The adenocarcinoma human alveolar basal epithelial cell line A549 was obtained from the
American Type Culture Collection (ATCC, Manassas, VA; ATCC #CCL-185) and cultured in
Kaighn's Modification of Ham's F-12 Medium (F-12K) supplemented with 10% fetal bovine
serum, 100 units/mL penicillin, and 100 µg/mL streptomycin. A549 cells were passaged every 4
days at a dilution of 1:7. Normal human bronchial epithelial cells (HBEC3-KT) were a kind gift
from Dr. John Minna at the University of Texas Southwestern Medical Center and have been
immortalized via the overexpression of cyclin-dependent kinase 4 (Cdk4) and human telomerase
reverse transcriptase (hTERT). HBEC3-KT are considered the best model for normal HBEC cells
as they do not form colonies in soft agar or tumors in nude mice.63  HBEC3-KT  cells  were
maintained in Keratinocyte-SFM supplemented with human recombinant Epidermal Growth
Factor and Bovine Pituitary Extract. HBEC3-KT cells were passaged every 5 days at a dilution of
1:4. All cells were cultured in an atmosphere of 95% air and 5% CO2 at 37°C in 100 mm culture
plates. Cultured cells with low passage numbers of 10−20 were used in the experiments to prevent
clonal selection of a cell strain that differed from the parental population. Cells were routinely
authenticated by short-terminal repeat DNA analysis and were mycoplasma-free (DNA
Diagnostics Center Medical, Fairfield, OH).
Detection of 3-ABA Formation in Cell Culture
The fluorescence of 3-ABA was used to measure the uptake and nitroreduction of non-fluorescent
3-NBA in cell culture. We adapted a 96-well fluorescence detection of 3-ABA reported by Pink
and colleagues.64 Metabolic assays with A549 cells were performed in 96-well plates 24 h (± 2 h)
after seeding of 1 × 104 A549 cells per well. After the 24 h attachment period, cells were treated
with 3-NBA in 0.1% DMSO (0.625 – 10 μM 3-NBA) in phenol red-free DMEM/F-12 (Dulbecco's
Modified Eagle Medium/Nutrient Mixture F-12). Excitation (λex) and emission (λem) wavelengths
for the Synergy 2 multi-detection microplate reader (Biotek Instruments Inc., Winooski, VT) were
set at 520 and 650 nm, respectively, based on the spectral properties of 3-ABA. Fluorescence was
monitored over a timespan from 1 h to 48 h. Cells treated with cell culture medium that contained
0.1% DMSO were used to correct for auto-fluorescence of the cells. Spontaneous formation of 3-
ABA was monitored in blank wells to determine background conversion rates of 3-NBA to 3-ABA
in a cell-free environment but were found to be non-significant. Formation of 3-ABA (pmol) was
quantified by using calibration curves constructed with authentic standards in phenol red-free
DMEM/F-12 media.
Metabolic  assays  with  HBEC3-KT cells  were  performed  in  96-well  plates  as  described  above
except  HBEC3-KT cells  rested  for  48  h  after  seeding  2  ×  104 cells per well before initiating
treatment. After the 48 h attachment period, cells were treated with 3-NBA in 0.1% DMSO (0.625
– 10 μM 3-NBA) in K-SFM. Fluorescence was monitored over a timespan from 1 h to 48 h.
Formation of 3-ABA (pmol) was quantified by using calibration curves constructed with authentic
standards in K-SFM.
To assess the contribution of individual enzymes, cells were treated with specific inhibitors prior
to and throughout the duration of exposure to 3-NBA. The following inhibitors were selected:
dicoumarol, NQO1 inhibitor;65 flufenamic acid, pan-AKR1C inhibitor;66 salicylic acid, AKR1C1
inhibitor;67-68 ursodeoxycholate, AKR1C2 inhibitor;69 indomethacin, AKR1C3 inhibitor;70
allopurinol, XO inhibitor;71 and rotenone, Complex I inhibitor72-73 to eliminate the contribution of
mitochondrial nitroreductases. To determine the optimal treatment conditions, six concentrations
between 0 – 100 µM were tested for each inhibitor to determine the lowest concentration in which
they produced maximal inhibition of 3-ABA formation. All assays were conducted in the 96-well
assays as described above with 2.5 µM 3-NBA. Cells were pretreated with inhibitors in 0.1%
DMSO or vehicle control (0.1% DMSO) for 1 h prior to exposure to 3-NBA. After the 1 h
incubation, cells were treated with 2.5 µM 3-NBA + the inhibitor in 0.15% DMSO. Control cells
were exposed to inhibitor only (0.15% DMSO) and used as blanks to correct for cellular auto-
fluorescence. We measured the effect of inhibitors on 3-ABA formation at 6 h for A549 cells and
24 h for HBEC3-KT cells. These time points were taken during a linear period of 3-ABA formation
and within the linear range of the calibration curves for 3-ABA detection in the respective cell
media.
Results
Activation of 3-nitrobenzanthrone by human aldo-keto reductases
Previous work by Guise et al. reported that AKR1C3 displayed nitroreductase activity towards the
chemotherapeutic agent PR-104A.53 To determine whether human AKR1C enzymes could display
nitroreductase activity towards nitrated polycyclic aromatic hydrocarbons (NO2-PAHs), we
investigated whether AKR1C1-1C4 would be able to metabolically activate 3-NBA.
Discontinuous enzymatic assays were initially performed with 1.68 μM enzyme (AKR1C1-1C4)
and 8.2 μM 3-NBA in potassium phosphate buffer pH 7 at 37 °C in a 2 mL system to screen for
nitroreductase activity. In order to characterize the reaction over time, 100 μL aliquots were
sampled at 15 min, 30 min, 45 min and at 1, 3, 6, 9, 18, and 24 h. An NADPH-regeneration system
consisting of glucose-6-phosphate (G6P) and glucose-6-phoshate dehydrogenase (G6PD) was
necessary to drive the reaction to completion within 24 hours. The disappearance of 3-NBA and
formation of the six-electron reduction product, 3-ABA, was monitored with reverse phase HPLC
coupled to in–line photo–diode–array (PDA) detection.
Figure 2. AKR1C3 catalyzes the nitroreduction of 3-NBA. 3-ABA was identified in
discontinuous assays with AKR1C3 using UV-HPLC monitoring at 279 nm (A). 3-NBA and 3-
ABA were identified based on retention times and UV spectra which were compared to standards.
3-NBA and 3-ABA levels were quantified over a 24 h time course (B). Results were similar for
AKR1C1, AKR1C2, and NQO1.
Under these conditions, 3-ABA appeared within 15 minutes after initiation with AKR1C1-1C3
and continued to increase in a time-dependent manner (Figure 2). 3-ABA formation was quantified
by integrating the peak that appeared at 27.2 minutes in the UV-chromatograms (Figure 2, A). The
observed 3-ABA formation was due to enzyme activity as less than 2% of 3-NBA is converted to
3-ABA in control reactions that lacked enzyme. Human recombinant AKR1A1, AKR1B1,
AKR1B10, AKR1D1, AKR7A2, and AKR7A3 were tested and were found to not contribute to
the nitroreduction of 3-NBA (data not shown). AKR1C4 possessed less than 10% of the
nitroreductase activity towards 3-NBA compared to AKR1C1-1C3 (data not shown).
UV-HPLC detection of 3-NBA and 3-ABA allowed us to determine that AKR1C enzymes
displayed nitroreductase activity, but the nitroso- and hydroxylamino- intermediates were not
identified in the UV-HPLC chromatograms. Evidence for the formation of the nitroso- and
hydroxylamino-intermediates and 3-ABA were instead obtained using UPLC-HRMS/MS. These
analytes gave exact mass within 5 ppm for the parent ion and the corresponding fragment ions in
the MS2 spectrum.
Figure 3. UPLC-HRMS/MS Detection of 3-NOBA. Aliquots of enzymatic reactions with
AKR1C1-1C3 and NQO1 were sampled at 0 h (left panels A, C) and 3 h (right panels B, D). Data
are shown for the reaction with AKR1C3 but are representative of each enzymatic reaction. 3-
NOBA MH+ was detected at m/z = 260.0706, and two fragments were identified: MH+-CO m/z =
232.0757 and MH+-NO m/z = 230.0729. 3-NOBA and its fragments were detected within 5 ppm
of their predicted m/z.
The two-electron reduction product, 3-NOBA, was identified in enzymatic reactions that contained
AKR1C1-1C3 and NQO1 at 3 h with m/z of 260.0710 and an elution time of 21.6 min (Figure 3).
Its fragment ion corresponding to the loss of the carbonyl (MH+-CO m/z = 232.0757) and loss of
the nitroso-group (MH+-NO m/z = 230.07290 were detected within ± 5 ppm. The hydroxylamino
intermediate N-OH-3-ABA (MH+ m/z = 262.0855) was also identified in reactions with AKR1C1-
1C3 and NQO1 at 3 h. It was identified in the pseudo-SRM chromatograms and eluted at 27.8-
27.9 min with m/z of 262.0867 (Figure 4). Its fragments corresponded to the loss of the hydroxyl
(MH+-OH m/z = 245.0835) and carbonyl (MH+-CO m/z = 234.0913) that were detected within the
given parameters (± 5 ppm).
Figure 4. UPLC-HRMS/MS Detection of N-OH-3-ABA. Aliquots of enzymatic reactions with
AKR1C1-1C3 and NQO1 were sampled at 0 h (left panels A, C) and 3 h (right panels B, D). Data
are shown for the reaction with AKR1C3 but are representative of each enzymatic reaction. N-
OH-3-ABA MH+ was detected at m/z = 262.0855, and two fragments were identified: MH+-OH
m/z = 245.0814 and MH+-CO m/z = 234.0895. N-OH-3-ABA and its fragments were detected
within 5 ppm of their predicted m/z.
Both the nitroso- and hydroxylamino-intermediates were unstable, and were subsequently detected
in low amounts, with intensities of 1.07E6 and 6.28E5, respectively. Much higher levels of the
product 3-ABA were detected with an intensity of 1.80E6 in the peak eluting at 18.03 min with
m/z of 246.0917 (Figure 5). 3-ABA was not detected by HRMS/MS in any enzymatic reactions at
the 0 h time point. Small amounts of both intermediates were detected at the 0 h time point
however, indicating either minimal contamination of 3-NBA or rapid conversion of 3-NBA to
these intermediates prior to organic extraction.
Figure 5. UPLC-HRMS/MS Detection of 3-ABA. Aliquots of enzymatic reactions with
AKR1C1-1C3 and NQO1 were sampled at 0 h (left panels A, C) and 3 h (right panels B, D). Data
are shown for the reaction with AKR1C3 but are representative of each enzymatic reaction. 3-
ABA MH+ was detected at m/z = 246.0919, and two fragments were identified:  MH+-NH2 m/z =
230.0729 and MH+-CO m/z = 218.0957. 3-ABA and its fragments were detected within 5 ppm of
their predicted m/z.
Comparison of AKR1C1-1C3 to NQO1
Since NQO1 had been previously identified as the major nitroreductase in the metabolic activation
of 3-NBA in vitro, we calculated Km, kcat, and catalytic efficiencies (kcat/Km) of AKR1C1-1C3 and
NQO1 to compare these enzymes for their ability to reduce 3-NBA and form 3-ABA. These assays
were optimized so that the amount of enzyme used was in the linear range for each protein as
determined by plots of initial velocity versus enzyme concentrations. Discontinuous enzymatic
assays with AKR1Cs were performed in 50 mM potassium phosphate buffer pH 7 at 37 °C in a 1
mL system using 0.5 µM AKR1C1-1C3 with 0 – 30 µM 3-NBA to construct v vs. [S] curves. To
capture the initial velocity during the first 5-10% of the reaction, multiple aliquots were taken in
the first 30 min. The formation of the six-electron reduction product, 3-ABA, was monitored with
reverse phase HPLC coupled to in–line PDA detection at 279 nm. Discontinuous enzymatic assays
with NQO1 were performed as described above with 0.25 µM NQO1. Initial velocity (v) vs. [S]
curves were fit with the Michaelis-Menten equation using GraphPad Prism 7.0 (GraphPad
Software, La Jolla, CA) to calculate Km and kcat, and kcat/Km (Figure 6). kcat/Km values were termed
“apparent catalytic efficiencies” since substrate concentrations were not significantly lower than
Km values due to the detection limits of this assay.
Figure 6. v vs. [S] curves for AKR1C1-1C3 and NQO1. Discontinuous enzymatic assays were
performed in 50 mM potassium phosphate buffer pH 7 at 37 °C in a 1 mL system using 0.5 µM
AKR1C1-1C3 or 0.25 µM NQO1 with 0 – 30 µM 3-NBA to construct v vs. [S] curves. Initial
velocity (v) vs. [S] curves were fit with the Michaelis-Menten equation using GraphPad Prism 7.0
to calculate Vmax, Km, and kcat.
We found that AKR1C1, AKR1C3, and NQO1 had very similar apparent catalytic efficiencies (~8
min-1 mM-1 vs. ~7 min-1 mM-1) despite the much higher kcat of NQO1 (0.058 min-1 vs. 0.012 min-
1). AKR1C1-1C3 possessed a much lower Km than NQO1: AKR1C1 and AKR1C3 had Km values
1.43 – 1.5 µM while the Km for NQO1 was 8.8 µM. AKR1C2 had a similar Km when compared to
AKR1C1 and AKR1C3 but had a lower kcat, and thus its apparent catalytic efficiency was 50%
less than AKR1C1 and AKR1C3. AKR1C4 was a very poor nitroreductase for 3-NBA and so it
was difficult to obtain steady state kinetic parameters for AKR1C4. AKR1C4 is a liver-specific
AKR1C isozyme and we expect that it will not contribute to 3-ABA formation in the lung.
Table 1. Catalytic Efficiencies for 3-NBA Turnover by NQO1 and AKR1C1-1C3
Recombinant
Enzyme
Km
(µM)
cat
(min-1)
cat/Km
(min-1 mM-1)
NQO1 8.8 ± 2.5 0.058 ± 0.0066 6.59
AKR1C1 1.5 ± 0.27 0.012 ± 0.0004 8.00
AKR1C2 1.1 ± 0.29 0.004 ± 0.0002 3.63
AKR1C3 1.4 ± 0.43 0.012 ± 0.0007 8.39
Relative contributions of AKR1C1-1C3 and NQO1 in vitro
Apparent catalytic efficiencies suggest that AKR1C1-1C3 may compete with NQO1 and
contribute to the nitroreduction of 3-NBA. To determine the relative contributions of these
enzymes in human lung epithelial cells, we modified a 96-well plate assay to monitor the formation
of 3-ABA in A549 cells.64 First we established that human lung cells metabolically activate 3-
NBA in submerged cell culture. A549 cells exposed to five different concentrations of 3-NBA
ranging from 0.625 – 10 mM revealed time- and dose-dependent formation of 3-ABA measured
by an increase of cellular fluorescence intensity compared to non-exposed cells. Elevated
fluorescence was observed by 60 min following exposure to 0.625 – 10 mM 3-NBA and increased
throughout the 48 h time course.
Figure 7.  3-ABA formation in A549 and HBEC3-KT cells. Determination of the metabolic
activation of 3-NBA to 3-ABA in A549 (A) and HBEC3-KT (B) cells. The intrinsic fluorescence
of 3-ABA (λex 520  nm,  λem 650 nm) was used to detect the final reduction product, 3-ABA.
Fluorescence was monitored over a timespan from 1 h to 48 h in A549 (n=3) and 1 h to 48 h in
HBEC3-KT (n=5). Elevated fluorescence levels were observed at 0.625 µM by 1 h in A549 cells
and by 6 h in HBEC3-KT.
HBEC3-KTs also metabolically activate 3-NBA and form 3-ABA in a time- and dose-dependent
manner. Due to the lower metabolic activity of this cell line and reduced sensitivity of 3-ABA
detection in K-SFM, the time to first detect an increase in fluorescence was 6 h, but this was below
the linear range of 3-ABA detection (Figure 7, B). Reliable measurements for formation of 3-ABA
after exposure to 0.625 – 10 µM 3-NBA concentrations could be obtained after 24 h and continued
to increase over 48 h.
To assess the contribution of NQO1 vs AKR1C1-1C3 in each cell line, we monitored the formation
of 3-ABA in the presence and absence of dicoumarol (a NQO1 inhibitor) and flufenamic acid (a
pan-AKR1C inhibitor). Together, these enzymes account for approximately 50% of the
nitroreduction of 3-NBA, and AKR1C enzymes make a significant contribution that is similar to
that of NQO1 in both cell lines, Fig. 8. Flufenamic acid reduced total 3-ABA formation by 34 ±
5% in A549 and 33 ± 7% in HBEC3-KT while dicoumarol reduced total 3-ABA formation by 23
± 6% in A549 and 40 ± 6% in HBEC3-KT. The combination treatment (10 µM dicoumarol + 50
µM flufenamic acid, abbreviated DF) led to 45 ± 8% reduction of 3-ABA formation in A549 and
53 ± 8% in HBEC3-KT.
Figure 8.  Inhibition of 3-ABA formation by AKR1C and NQO1 inhibitors. Specific inhibitors
were used to assess individual contributions of AKR1C1-1C3, NQO1, XO, and complex 1 in
catalyzing nitroreduction of 3-NBA in A549 and HBEC3-KT cell lines exposed to 2.5 µM 3-NBA.
Abbreviations used: Dic, Dicoumarol; FA, Flufenamic Acid; DF, combination treatment with
Dicoumarol and Flufenamic Acid; SA, Salicylic Acid; Urso, Ursodeoxycholate; Indo,
Indomethacin; Allo, Allopurinol; and Rot, Rotenone. Experiments were repeated at least 5
independent times (n = 5-7).
To further assess the role of individual AKR1C enzymes, salicylic acid was selected as a specific
inhibitor against AKR1C1 (IC50: 5.8 µM), ursodeoxycholate is a specific inhibitor against
AKR1C2 (IC50: 236 nM), and indomethacin is a specific inhibitor against AKR1C3 (IC50: 108
nM). Several concentrations between 0 – 100 µM were tested for each inhibitor to determine the
lowest concentration in which they produced maximal inhibition of 3-ABA formation. Salicylic
acid inhibited 3-ABA formation by approximately 18% in A549 cells and 4% in HBEC3-KT,
ursodeoxycholate inhibited 3-ABA formation by approximately 33% in A549 cells and 5% in
HBEC3-KT, and indomethacin inhibited 3-ABA formation by approximately 5% in A549 cells
and 19% in HBEC3-KT.
Allopurinol (XO inhibitor) was included in the inhibitor screen as XO has been previously
implicated in the reduction of 3-NBA.37 XO plays a minor role in the metabolic activation of 3-
NBA and contributes approximately 9-11% of 3-ABA formation in A549 and HBEC3-KT cell
lines. Rotenone was included to rule out contribution of mitochondrial nitroreductases as it is a
Complex I inhibitor. Rotenone inhibits approximately 12% of total 3-ABA formation in A549 and
HBEC3-KT cells, but with high variability. It is likely that mitochondrial nitroreductases play a
minor role in the formation of 3-ABA.
Discussion
3-NBA is a potent mutagen and suspected human carcinogen present in diesel engine exhaust and
ambient air particulate matter which requires metabolic activation in order to promote its
mutagenic and tumorigenic effects.8-14, 22, 74 Previous research has suggested that NQO1 is the
major nitroreductase responsible for 3-NBA activation, but this work has largely been conducted
in human hepatic cytosols51 and primary human hepatocytes49 which may not be reflective of 3-
NBA bioactivation following inhalation exposures. To further characterize the metabolic
activation of 3-NBA, we examined the role of human AKR enzymes due to reports that AKR1C3
nitroreductase activity superseded that of NQO1 towards the cancer therapeutic PR-104A.53
AKR1C genes are also among the most upregulated genes in non-small cell lung cancer and in
bronchial epithelial cells exposed to environmental carcinogens.53, 79-83
We established the ability of AKR1C1-1C3 to act as nitroreductases via detection of the final
reduction product 3-ABA in discontinuous enzymatic assays using HPLC-UV chromatography,
and a product-precursor relationship was established. We found evidence for the formation of the
nitroso- and hydroxylamino-intermediates via UPLC-HRMS, but these intermediates were not
produced in significant quantities which suggests that these intermediates are unstable or are
quickly metabolized to 3-ABA, the final reduction product. The ability of AKR1C enzymes to
catalyze the reduction of 3-NBA and sequentially generate the nitroso- and hydroxylamino-
intermediates is unusual since the AKRs conduct a single 2-electron reduction of carbonyl groups
followed by the ordered release of reduced product and NADP+.84 This is the first time to our
knowledge that AKR1C enzymes have been implicated in the metabolic activation of NO2-PAHs
by acting as nitroreductases.
The present study examined AKR1C1-1C3 and NQO1 in cell-free systems to compare their kinetic
constants (Km, kcat, kcat/Km). We found that the apparent catalytic efficiencies (kcat/Km) for 3-ABA
formation were nearly equivalent for AKR1C1, AKR1C3, and NQO1. Other AKR1C isozymes
have variable nitroreductase activity towards 3-NBA: AKR1C2 had a lower kcat/Km than AKR1C1
and AKR1C3 while liver-specific AKR1C4 had negligible nitroreductase activity. kcat/Km is best
applied to measure catalytic efficiency when the substrate concentrations cover the range 0.2-5.0
Km, but this was not achieved due our limitations in detecting 3-ABA in the low substrate range.
Our lower limit of detection of 3-ABA was 0.005 nmol, which required higher substrate
concentrations (1 – 30 µM) in the reaction system to form sufficient quantities of 3-ABA within
the period that 3-ABA formation was linear with time. Despite these limitations, these apparent
catalytic efficiencies are a useful comparator of the abilities of AKR1C1-1C3 and NQO1 to reduce
3-NBA. Although NQO1 has a higher turnover rate, AKR1Cs possess much lower Km values than
NQO1. The low Km observed with AKR1C enzymes suggests that that they may be more important
than NQO1 at the low concentrations of 3-NBA to which humans are exposed by inhalation.
We chose to evaluate the relative importance of AKR1C1-1C3 and NQO1 in human lung epithelial
cell lines as the respiratory tract is the primary site of exposure to 3-NBA. 3-NBA-induced DNA
adduct formation (i.e. 3-NBA activation) has also been observed in cultured human A54946, 75-76,
TT116 and BEAS-2B77-78 lung cell lines. Our data suggest that the combined activities of AKR1C1-
1C3 and NQO1 contribute equally in the reduction of 3-NBA in A549 and HBEC3-KT cell lines.
Flufenamic acid, a pan-AKR1C inhibitor, and dicoumarol, a NQO1 inhibitor, reduced 3-ABA
formation in cell culture to a similar extent in both cell lines. Although the contribution of NQO1
to the total nitroreductase activity is greater than any single AKR1C enzyme, the combined
activities of AKR1C1-1C3 are roughly equivalent to NQO1 in these lung cell lines. However, the
contribution of individual AKR1C isozymes may differ between cell lines. The use of specific
inhibitors against individual AKR1C enzymes (salicylic acid, ursodeoxycholate, and
indomethacin) suggests that AKR1C2 contributes to a much greater percentage of 3-NBA
reduction than AKR1C1 and AKR1C3 in A549 cells while AKR1C3 appears to be the dominant
isozyme in HBEC3-KT cells. This may be due to variability in relative expression of AKR1C1-
1C3 between cell lines.
A549 cells displayed greater nitroreductase activity towards 3-NBA than HBEC3-KT cells which
is to be expected since A549 cells have higher levels of AKR1C1-1C3 and NQO1 due to
constitutively active nuclear factor (erythroid-derived 2)-like 2 (Nrf2).85-86 AKR1C and NQO1
genes are induced by the Nrf2-Keap1 pathway and possess antioxidant response elements (ARE)
in their promoters. AKR1C1-AKR1C3 genes contain multiple AREs (6-16 based on a positional
matrix search) in their promoters and are among the most highly induced genes by the Nrf2-Keap1
system in humans yet the least studied.84, 89-92 NQO1 is a prototypic Nrf2-regulated gene which is
induced by exposures to NO2-PAHs, and so it is thought that NO2-PAHs may induce their own
genotoxicity by increasing transcription of NQO1.52, 87-88 A similar phenomena is observed in the
metabolic activation of PAH by AKRs as their reactive metabolites (PAH ortho-quinones, ROS)
upregulate Nrf2 and further upregulate AKR1C genes, thus enhancing PAH bioactivation and
genotoxicity. 89, 93 AKR1C genes are also part of the “smoking gene battery” – genes that are
upregulated in bronchial epithelial cells of smokers and are downregulated in smokers who have
quit.80-83 Interestingly, Nrf-targeted chemopreventatives such as R-sulforaphane (R-SFN) induce
AKR1C and NQO1 genes.89 Given the similarities in the induction of AKR1C1-1C3 and NQO1,
both gene families will likely be over-expressed during exposures to NO2-PAHs which will
exacerbate metabolic activation of these compounds. This raises the question about the safety of
indiscriminate use of Nrf2-targeted chemoprevention therapies as there may be certain
environmental exposures that are toxified by Nrf2 activity.
Our data from this study suggest that monitoring expression of both NQO1 and AKR1C1-1C3
may provide insight into ability of cells and tissues to bioactivate 3-NBA. Human AKR1C
isozymes have been previously implicated in the metabolic activation of PAHs via their
dihydrodiol dehydrogenase activity to produce electrophilic and redox-active ortho-quinones.94-98
However, our work suggests for the first time that they may also be important for the metabolic
activation of NO2-PAHs via nitroreductase activity.
Funding Sources
This publication was made possible by the Pharmaceutical Research and Manufacturers of
America (PhRMA) Foundation Pharmacology/Toxicology Pre-Doctoral Fellowship (J.R.M.) and
P30 ES013508 (T.M.P.) and T32019851 (J.R.M.) from the National Institute of Environmental
Health Sciences (NIEHS), NIH, DHHS. Its contents are solely the responsibility of the authors and
do not necessarily represent the official views of the NIEHS or NIH. Work at King’s College
London is supported by the National Institute for Health Research Health Protection Research Unit
(NIHR  HPRU)  in  Health  Impact  of  Environmental  Hazards  at  King’s  College  London  in
partnership with Public Health England (PHE) and Imperial College London. The views expressed
are those of the authors and not necessarily those of the UK National Health Service, the NIHR,
the UK Department of Health & Social Care or PHE.
Notes
The authors declare no competing financial interest.
Abbreviations
NO2-PAHs, nitrated polycyclic aromatic hydrocarbons; PAHs, polycyclic aromatic hydrocarbons;
3-NBA, 3-nitrobenzanthrone; 3-NOBA, 3-nitrosobenzanthrone; N-OH-3-ABA, N-hydroxy-3-
aminobenzanthrone; 3-ABA, 3-aminobenzanthrone; Dic, dicoumarol; FA, flufenamic acid; AKR,
aldo-keto reductase; NQO1, NAD(P)H:quinone oxidoreductase 1; XO, xanthine oxidase;  nuclear
factor (erythroid-derived 2)-like 2, Nrf2
References
1. Esposito, L.; Conti, D.; Ailavajhala, R.; Khalil, N.; Giordano, A., Lung Cancer: Are we up
to the Challenge? Current Genomics 2010, 11 (7), 513-8.
2. Fontham, E. T.; Correa, P.; Reynolds, P.; Wu-Williams, A.; Buffler, P. A.; Greenberg, R.
S.; Chen, V. W.; Alterman, T.; Boyd, P.; Austin, D. F.; et al., Environmental tobacco smoke and
lung cancer in nonsmoking women. A multicenter study. Jama 1994, 271 (22), 1752-9.
3. Doll, R.; Hill, A. B., Lung Cancer and Other Causes of Death in Relation to Smoking. Br
Med J 1956, 2 (5001), 1071-81.
4. Loomis, D.; Grosse, Y.; Lauby-Secretan, B.; Ghissassi, F. E.; Bouvard, V.; Benbrahim-
Tallaa, L.; Guha, N.; Baan, R.; Mattock, H.; Straif, K., The carcinogenicity of outdoor air pollution.
The Lancet Oncology 2013, 14 (13), 1262-1263.
5. Brauer, M.; Amann, M.; Burnett, R. T.; Cohen, A.; Dentener, F.; Ezzati, M.; Henderson,
S. B.; Krzyzanowski, M.; Martin, R. V.; Van Dingenen, R.; van Donkelaar, A.; Thurston, G. D.,
Exposure assessment for estimation of the global burden of disease attributable to outdoor air
pollution. Environ Sci Technol 2012, 46 (2), 652-60.
6. Vineis, P.; Forastiere, F.; Hoek, G.; Lipsett, M., Outdoor air pollution and lung cancer:
recent epidemiologic evidence. Int J Cancer 2004, 111 (5), 647-52.
7. Straif, K.; Cohen, A.; Samet, J., IARC Scientific Publications. Air Pollution and Cancer.
2013; Vol. 161.
8. IARC, Diesel and gasoline engine exhausts and some nitroarenes. IARC Monographs on
the Evaluation of Carcinogenic Risks to Humans 2012, 105.
9. Attfield, M. D.; Schleiff, P. L.; Lubin, J. H.; Blair, A.; Stewart, P. A.; Vermeulen, R.;
Coble, J. B.; Silverman, D. T., The Diesel Exhaust in Miners study: a cohort mortality study with
emphasis on lung cancer. J Natl Cancer Inst 2012, 104 (11).
10.  Garshick,  E.;  Schenker,  M.  B.;  Munoz,  A.;  Segal,  M.;  Smith,  T.  J.;  Woskie,  S.  R.;
Hammond, S. K.; Speizer, F. E., A case-control study of lung cancer and diesel exhaust exposure
in railroad workers. Am Rev Respir Dis 1987, 135 (6), 1242-8.
11. Garshick, E.; Laden, F.; Hart, J. E.; Rosner, B.; Smith, T. J.; Dockery, D. W.; Speizer, F.
E., Lung cancer in railroad workers exposed to diesel exhaust. Environ Health Perspect 2004, 112
(15), 1539-1543.
12. Tokiwa, H.; Sera, N.; Horikawa, K.; Nakanishi, Y.; Shigematu, N., The presence of
mutagens/carcinogens in the excised lung and analysis of lung cancer induction. Carcinogenesis
1993, 14 (9), 1933-8.
13. Vermeulen, R.; Silverman, D. T.; Garshick, E.; Vlaanderen, J.; Portengen, L.; Steenland,
K., Exposure-response estimates for diesel engine exhaust and lung cancer mortality based on data
from three occupational cohorts. Environ Health Perspect 2014, 122 (2), 172-7.
14. Silverman, D. T.; Samanic, C. M.; Lubin, J. H.; Blair, A. E.; Stewart, P. A.; Vermeulen,
R.; Coble, J. B.; Rothman, N.; Schleiff, P. L.; Travis, W. D.; Ziegler, R. G.; Wacholder, S.;
Attfield, M. D., The Diesel Exhaust in Miners study: a nested case-control study of lung cancer
and diesel exhaust. J Natl Cancer Inst 2012, 104 (11), 855-68.
15. Boström, C.-E. E.; Gerde, P.; Hanberg, A.; Jernström, B.; Johansson, C.; Kyrklund, T.;
Rannug, A.; Törnqvist, M.; Victorin, K.; Westerholm, R., Cancer risk assessment, indicators, and
guidelines for polycyclic aromatic hydrocarbons in the ambient air. Environ Health Perspect 2002,
110 Suppl 3, 451-488.
16. Jarvis, I. W. H.; Enlo-Scott, Z.; Nagy, E.; Mudway, I. S.; Tetley, T. D.; Arlt, V. M.; Phillips,
D. H., Genotoxicity of fine and coarse fraction ambient particulate matter in immortalised normal
(TT1) and cancer-derived (A549) alveolar epithelial cells. Environ Mol Mutagen 2018, 59 (4),
290-301.
17. Tokiwa, H.; Ohnishi, Y.; Rosenkranz, H. S., Mutagenicity and carcinogenicity of
nitroarenes and their sources in the environment. Crit Rev Toxicol 1986, 17 (1), 23-60.
18. Samet, J. M.; Avila-Tang, E.; Boffetta, P.; Hannan, L. M.; Olivo-Marston, S.; Thun, M. J.;
Rudin, C. M., Lung cancer in never smokers: clinical epidemiology and environmental risk factors.
Clin Cancer Res 2009, 15 (18), 5626-45.
19. Boffetta, P.; Nyberg, F., Contribution of environmental factors to cancer risk. British
medical bulletin 2003, 68, 71-94.
20. Benbrahim-Tallaa, L.; Baan, R. A.; Grosse, Y.; Lauby-Secretan, B.; El Ghissassi, F.;
Bouvard, V.; Guha, N.; Loomis, D.; Straif, K., Carcinogenicity of diesel-engine and gasoline-
engine exhausts and some nitroarenes. The Lancet. Oncology 2012, 13 (7), 663-4.
21. Arlt, V. M., 3-Nitrobenzanthrone, a potential human cancer hazard in diesel exhaust and
urban air pollution: a review of the evidence. Mutagenesis 2005, 20 (6), 399-410.
22. Enya, T.; Suzuki, H.; Watanabe, T.; Hirayama, T.; Hisamatsu, Y., 3-Nitrobenzanthrone, a
Powerful Bacterial Mutagen and Suspected Human Carcinogen Found in Diesel Exhaust and
Airborne Particulates. Environ Sci Technol 1997, 31 (10), 2772-2776.
23. Takamura-Enya, T.; Suzuki, H.; Hisamatsu, Y., Mutagenic activities and physicochemical
properties of selected nitrobenzanthrones. Mutagenesis 2006, 21 (6), 399-404.
24. Nagy, E.; Zeisig, M.; Kawamura, K.; Hisamatsu, Y.; Sugeta, A.; Adachi, S.; Moller, L.,
DNA adduct and tumor formations in rats after intratracheal administration of the urban air
pollutant 3-nitrobenzanthrone. Carcinogenesis 2005, 26 (10), 1821-8.
25. Arlt, V. M.; Zhan, L.; Schmeiser, H. H.; Honma, M.; Hayashi, M.; Phillips, D. H.; Suzuki,
T., DNA adducts and mutagenic specificity of the ubiquitous environmental pollutant 3-
nitrobenzanthrone in Muta Mouse. Environ Mol Mutagen 2004, 43 (3), 186-95.
26. Arlt, V. M.; Gingerich, J.; Schmeiser, H. H.; Phillips, D. H.; Douglas, G. R.; White, P. A.,
Genotoxicity of 3-nitrobenzanthrone and 3-aminobenzanthrone in MutaMouse and lung epithelial
cells derived from MutaMouse. Mutagenesis 2008, 23 (6), 483-490.
27. White, P. A.; Douglas, G. R.; Phillips, D. H.; Arlt, V. M., Quantitative relationships
between lacZ mutant frequency and DNA adduct frequency in MutaMouse tissues and cultured
cells exposed to 3-nitrobenzanthrone. Mutagenesis 2017, 32 (2), 299-312.
28. Kucab, J. E.; Zwart, E. P.; van Steeg, H.; Luijten, M.; Schmeiser, H. H.; Phillips, D. H.;
Arlt, V. M., TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human
TP53 knock-in mouse embryo fibroblasts. DNA Repair (Amst) 2015.
29. Fu, P. P., Metabolism of nitro-polycyclic aromatic hydrocarbons. Drug Metab Rev 1990,
22 (2-3), 209-68.
30. IARC, Diesel and gasoline engine exhausts and some nitroarenes. IARC Monographs on
the Evaluation of Carcinogenic Risks to Humans 1989, 46, 1-458.
31. Arlt, V. M.; Glatt, H.; Muckel, E.; Pabel, U.; Sorg, B. L.; Seidel, A.; Frank, H.; Schmeiser,
H. H.; Phillips, D. H., Activation of 3-nitrobenzanthrone and its metabolites by human
acetyltransferases, sulfotransferases and cytochrome P450 expressed in Chinese hamster V79
cells. Int J Cancer 2003, 105 (5), 583-92.
32. Arlt, V. M.; Glatt, H.; Muckel, E.; Pabel, U.; Sorg, B. L.; Schmeiser, H. H.; Phillips, D. H.,
Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human
acetyltransferases and sulfotransferase. Carcinogenesis 2002, 23 (11), 1937-1945.
33. Arlt, V. M.; Stiborova, M.; Hewer, A.; Schmeiser, H. H.; Phillips, D. H., Human enzymes
involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone:
evidence for reductive activation by human NADPH:cytochrome p450 reductase. Cancer Res
2003, 63 (11), 2752-2761.
34. Arlt, V. M.; Sorg, B. L.; Osborne, M.; Hewer, A.; Seidel, A.; Schmeiser, H. H.; Phillips,
D. H., DNA adduct formation by the ubiquitous environmental pollutant 3-nitrobenzanthrone and
its metabolites in rats. Biochem Biophys Res Commun 2003, 300 (1), 107-114.
35. Bieler, C. A.; Wiessler, M.; Erdinger, L.; Suzuki, H.; Enya, T.; Schmeiser, H. H., DNA
adduct formation from the mutagenic air pollutant 3-nitrobenzanthrone. Mutat Res 1999, 439 (2),
307-11.
36. Stiborova, M.; Frei, E.; Schmeiser, H. H.; Arlt, V. M.; Martinek, V., Mechanisms of
enzyme-catalyzed reduction of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and
aristolochic acid I: Experimental and theoretical approaches. Int J Mol Sci 2014, 15 (6), 10271-95.
37. Arlt, V. M.; Henderson, C. J.; Wolf, C. R.; Schmeiser, H. H.; Phillips, D. H.; Stiborova,
M., Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-
nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes
and peroxidases. Cancer letters 2006, 234 (2), 220-231.
38. Arlt, V. M.; Hewer, A.; Sorg, B. L.; Schmeiser, H. H.; Phillips, D. H.; Stiborova, M., 3-
aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone,
forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for
activation by cytochrome P450 1A1 and P450 1A2. Chemical research in toxicology 2004, 17 (8),
1092-1101.
39. Arlt, V. M.; Bieler, C. A.; Mier, W.; Wiessler, M.; Schmeiser, H. H., DNA adduct
formation by the ubiquitous environmental contaminant 3-nitrobenzanthrone in rats determined by
32P-postlabeling. Int J Cancer 2001, 93 (3), 450-454.
40.  Bieler,  C.  A.;  Cornelius,  M.  G.;  Klein,  R.;  Arlt,  V.  M.;  Wiessler,  M.;  Phillips,  D.  H.;
Schmeiser, H. H., DNA adduct formation by the environmental contaminant 3-nitrobenzanthrone
after intratracheal instillation in rats. Int J Cancer 2005, 116 (6), 833-8.
41. Arlt, V. M.; Schmeiser, H. H.; Osborne, M. R.; Kawanishi, M.; Kanno, T.; Yagi, T.;
Phillips, D. H.; Takamura-Enya, T., Identification of three major DNA adducts formed by the
carcinogenic air pollutant 3-nitrobenzanthrone in rat lung at the C8 and N2 position of guanine
and at the N6 position of adenine. International journal of cancer. 2006, 118 (9), 2139-2146.
42. Arlt, V. M.; Meinl, W.; Florian, S.; Nagy, E.; Barta, F.; Thomann, M.; Mrizova, I.; Krais,
A. M.; Liu, M.; Richards, M.; Mirza, A.; Kopka, K.; Phillips, D. H.; Glatt, H.; Stiborova, M.;
Schmeiser, H. H., Impact of genetic modulation of SULT1A enzymes on DNA adduct formation
by aristolochic acids and 3-nitrobenzanthrone. Arch Toxicol 2017, 91 (4), 1957-1975.
43. Kanno, T.; Kawanishi, M.; Takamura-Enya, T.; Arlt, V. M.; Phillips, D. H.; Yagi, T., DNA
adduct formation in human hepatoma cells treated with 3-nitrobenzanthrone: analysis by the (32)P-
postlabeling method. Mutation research 2007, 634 (1-2), 184-191.
44.  Lamy,  E.;  Kassie,  F.;  Gminski,  R.;  Schmeiser,  H.  H.;  Mersch-Sundermann,  V.,  3-
Nitrobenzanthrone (3-NBA) induced micronucleus formation and DNA damage in human
hepatoma (HepG2) cells. Toxicol Lett 2004, 146 (2), 103-9.
45. Phousongphouang, P. T.; Grosovsky, A. J.; Eastmond, D. A.; Covarrubias, M.; Arey, J.,
The genotoxicity of 3-nitrobenzanthrone and the nitropyrene lactones in human lymphoblasts.
Mutat Res 2000, 472 (1-2), 93-103.
46. Arlt, V. M.; Glatt, H.; Gamboa da Costa, G.; Reynisson, J.; Takamura-Enya, T.; Phillips,
D. H., Mutagenicity and DNA adduct formation by the urban air pollutant 2-nitrobenzanthrone.
Toxicol Sci 2007, 98 (2), 445-57.
47. Seidel, A.; Dahmann, D.; Krekeler, H.; Jacob, J., Biomonitoring of polycyclic aromatic
compounds in the urine of mining workers occupationally exposed to diesel exhaust. Int J Hyg
Environ Health 2002, 204 (5-6), 333-8.
48.  Stiborova,  M.;  Arlt,  V.  M.;  Henderson,  C.  J.;  Wolf,  C.  R.;  Frei,  E.;  Schmeiser,  H.  H.;
Phillips, D. H., Molecular mechanism of genotoxicity of the environmental pollutant 3-
nitrobenzanthrone. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc,
Czechoslovakia 2005, 149 (2), 191-7.
49. Stiborová, M.; Martínek, V.; Svobodová, M.; Sístková, J.; Dvorák, Z.; Ulrichová, J.;
Simánek, V.; Frei, E.; Schmeiser, H. H.; Phillips, D. H.; Arlt, V. M., Mechanisms of the different
DNA adduct forming potentials of the urban air pollutants 2-nitrobenzanthrone and carcinogenic
3-nitrobenzanthrone. Chem Res Toxicol 2010, 23 (7), 1192-1201.
50.  Arlt,  V.  M.;  Stiborova,  M.;  Henderson,  C.  J.;  Osborne,  M.  R.;  Bieler,  C.  A.;  Frei,  E.;
Martinek, V.; Sopko, B.; Wolf, C. R.; Schmeiser, H. H.; Phillips, D. H., Environmental pollutant
and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by
NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in
human hepatic cytosols. Cancer Res 2005, 65 (7), 2644-52.
51.  Arlt,  V.  M.;  Stiborova,  M.;  Henderson,  C.  J.;  Osborne,  M.  R.;  Bieler,  C.  A.;  Frei,  E.;
Martinek, V.; Sopko, B.; Wolf, R. C.; Schmeiser, H. H.; Phillips, D. H., Environmental Pollutant
and Potent Mutagen 3-Nitrobenzanthrone Forms DNA Adducts after Reduction by
NAD(P)H:Quinone Oxidoreductase and Conjugation by Acetyltransferases and Sulfotransferases
in Human Hepatic Cytosols. Cancer Research 2005, 65 (7), 2644-2652.
52. Stiborová, M.; Dracínská, H.; Hájková, J.; Kaderábková, P.; Frei, E.; Schmeiser, H. H.;
Soucek, P.; Phillips, D. H.; Arlt, V. M., The environmental pollutant and carcinogen 3-
nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat
hepatic cytochromes P450 1A1 and -1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab
Dispos 2006, 34 (8), 1398-1405.
53. Guise, C. P.; Abbattista, M. R.; Singleton, R. S.; Holford, S. D.; Connolly, J.; Dachs, G.
U.; Fox, S. B.; Pollock, R.; Harvey, J.; Guilford, P.; Donate, F.; Wilson, W. R.; Patterson, A. V.,
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto
reductase 1C3. Cancer Res 2010, 70 (4), 1573-84.
54. Penning, T. M., Aldo-Keto Reductases. In Comprehensive Toxicology, McQueen, C. A.,
Ed. Academic Press: Oxford, 2010; Vol. 4, pp 149-167.
55. Penning, T. M.; Drury, J. E., Human aldo–keto reductases: Function, gene regulation, and
single nucleotide polymorphisms. Arch Biochem Biophys 2007, 464 (2), 241-250.
56. Hsu, N. Y.; Ho, H. C.; Chow, K. C.; Lin, T. Y.; Shih, C. S.; Wang, L. S.; Tsai, C. M.,
Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung
cancer. Cancer Res 2001, 61 (6), 2727-31.
57. Arlt, V. M.; Glatt, H.; Muckel, E.; Pabel, U.; Sorg, B. L.; Schmeiser, H. H.; Phillips, D. H.,
Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human
acetyltransferases and sulfotransferase. Carcinogenesis 2002, 23 (11), 1937-45.
58. Schmeiser, H. H.; Furstenberger, G.; Takamura-Enya, T.; Phillips, D. H.; Arlt, V. M., The
genotoxic air pollutant 3-nitrobenzanthrone and its reactive metabolite N-hydroxy-3-
aminobenzanthrone lack initiating and complete carcinogenic activity in NMRI mouse skin.
Cancer Lett 2009, 284 (1), 21-9.
59.  Fifer,  E.  K.;  Heflich,  R.  H.;  Djurić,  Z.;  Howard,  P.  C.;  Beland,  F.  A.,  Synthesis  and
mutagenicity of 1-nitro-6-nitrosopyrene and 1-nitro-8-nitrosopyrene, potential intermediates in the
metabolic activation of 1,6- and 1,8-dinitropyrene. Carcinogenesis 1986, 7 (1), 65-70.
60. Penning, T. M.; Burczynski, M. E.; Jez, J. M.; Hung, C. F.; Lin, H. K.; Ma, H.; Moore, M.;
Palackal, N.; Ratnam, K., Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-
AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution
reveals roles in the inactivation and formation of male and female sex hormones. The Biochemical
journal 2000, 351 (Pt 1), 67-77.
61. Adeniji, A.; Uddin, M. J.; Zang, T.; Tamae, D.; Wangtrakuldee, P.; Marnett, L. J.; Penning,
T. M., Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective
Aldo-keto Reductase 1C3 Inhibitor. Journal of Medicinal Chemistry 2016, 59 (16), 7431-7444.
62. Burczynski, M. E.; Harvey, R. G.; Penning, T. M., Expression and characterization of four
recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-
dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione.
Biochemistry 1998, 37 (19), 6781-6790.
63. Ramirez, R. D.; Sheridan, S.; Girard, L.; Sato, M.; Kim, Y.; Pollack, J.; Peyton, M.; Zou,
Y.; Kurie, J. M.; Dimaio, J. M.; Milchgrub, S.; Smith, A. L.; Souza, R. F.; Gilbey, L.; Zhang, X.;
Gandia,  K.;  Vaughan,  M.  B.;  Wright,  W.  E.;  Gazdar,  A.  F.;  Shay,  J.  W.;  Minna,  J.  D.,
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer
res 2004, 64 (24), 9027-9034.
64. Pink, M.; Verma, N.; Zerries, A.; Schmitz-Spanke, S., Dose-Dependent Response to 3-
Nitrobenzanthrone Exposure in Human Urothelial Cancer Cells. Chem Res Toxicol 2017, 30 (10),
1855-1864.
65. Ernster, L.; Ljunggren, M.; Danielson, L., Purification and some properties of a highly
dicumarol-sensitive liver diaphorase. Biochemical and Biophysical Research Communications
1960, 2 (2), 88-92.
66. Steckelbroeck, S.; Jin, Y.; Gopishetty, S.; Oyesanmi, B.; Penning, T. M., Human Cytosolic
3α-Hydroxysteroid Dehydrogenases of the Aldo-keto Reductase Superfamily Display Significant
3β-Hydroxysteroid Dehydrogenase Activity: IMPLICATIONS FOR STEROID HORMONE
METABOLISM AND ACTION. Journal of Biological Chemistry 2004, 279 (11), 10784-10795.
67. Byrns, M. C.; Penning, T. M., Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin
F Synthase (AKR1C3): Role In Breast Cancer and Inhibition by Nonsteroidal Antiinflammatory
Drug Analogs. Chem Biol Interact 2009, 178 (1-3), 221-7.
68. Dhagat, U.; Carbone, V.; Chung, R. P.; Matsunaga, T.; Endo, S.; Hara, A.; El-Kabbani, O.,
A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human
20alpha-hydroxysteroid dehydrogenase. Medicinal chemistry (Shariqah (United Arab Emirates))
2007, 3 (6), 546-50.
69. Hara, A.; Matsuura, K.; Tamada, Y.; Sato, K.; Miyabe, Y.; Deyashiki, Y.; Ishida, N.,
Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and
an oxidoreductase of human colon cells. Biochemical Journal 1996, 313 (Pt 2), 373-6.
70. Byrns, M. C.; Steckelbroeck, S.; Penning, T. M., An indomethacin analogue, N-(4-
chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD,
type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone
dependent and hormone independent malignancies. Biochem Pharmacol 2008, 75 (2), 484-93.
71. Watts, R. W. E.; Watts, J. E. M.; Seegmiller, J. E., Xanthine oxidase activity in human
tissues and its inhibition by allopurinol (4-hydroxypyrazolo[3,4-d] pyrimidine). The Journal of
Laboratory and Clinical Medicine 1965, 66 (4), 688-697.
72. Oberg, K. E., The site of the action of rotenone in the respiratory chain. Exp Cell Res 1961,
24, 163-4.
73. Palmer, G.; Horgan, D. J.; Tisdale, H.; Singer, T. P.; Beinert, H., Studies on the respiratory
chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. XIV. Location of the sites
of inhibition of rotenone, barbiturates, and piericidin by means of electron paramagnetic resonance
spectroscopy. J Biol Chem 1968, 243 (4), 844-7.
74.  Arlt,  V.  M.;  Stiborova,  M.;  Henderson,  C.  J.;  Osborne,  M.  R.;  Bieler,  C.  A.;  Frei,  E.;
Martinek, V.; Sopko, B.; Wolf, R. C.; Schmeiser, H. H.; Phillips, D. H., Environmental Pollutant
and Potent Mutagen 3-Nitrobenzanthrone Forms DNA Adducts after Reduction by
NAD(P)H:Quinone Oxidoreductase and Conjugation by Acetyltransferases and Sulfotransferases
in Human Hepatic Cytosols. Cancer Res 2005, 65 (7), 2644-2652.
75. Nagy, E.; Adachi, S.; Takamura-Enya, T.; Zeisig, M.; Moller, L., DNA adduct formation
and oxidative stress from the carcinogenic urban air pollutant 3-nitrobenzanthrone and its isomer
2-nitrobenzanthrone, in vitro and in vivo. Mutagenesis 2007, 22 (2), 135-45.
76. Rossner, P.; Strapacova, S.; Stolcpartova, J.; Schmuczerova, J.; Milcova, A.; Neca, J.;
Vlkova, V.; Brzicova, T.; Machala, M.; Topinka, J., Toxic effects of the major components of
diesel exhaust in human alveolar basal epithelial cells (A549). Int J Mol Sci 2016, 17 (9).
77. Oya, E.; Ovrevik, J.; Arlt, V. M.; Nagy, E.; Phillips, D. H.; Holme, J. A., DNA damage
and DNA damage response in human bronchial epithelial BEAS-2B cells following exposure to
2-nitrobenzanthrone and 3-nitrobenzanthrone: role in apoptosis. Mutagenesis 2011, 26 (6), 697-
708.
78. Ovrevik, J.; Arlt, V. M.; Oya, E.; Nagy, E.; Mollerup, S.; Phillips, D. H.; Lag, M.; Holme,
J. A., Differential effects of nitro-PAHs and amino-PAHs on cytokine and chemokine responses
in human bronchial epithelial BEAS-2B cells. Toxicol Appl Pharmacol 2010, 242 (3), 270-80.
79. MacLeod, A. K.; Acosta-Jimenez, L.; Coates, P. J.; McMahon, M.; Carey, F. A.; Honda,
T.; Henderson, C. J.; Wolf, C. R., Aldo-keto reductases are biomarkers of NRF2 activity and are
co-ordinately overexpressed in non-small cell lung cancer. Br J Cancer 2016, 115 (12), 1530-9.
80. Woenckhaus, M.; Klein-Hitpass, L.; Grepmeier, U.; Merk, J.; Pfeifer, M.; Wild, P.;
Bettstetter, M.; Wuensch, P.; Blaszyk, H.; Hartmann, A.; Hofstaedter, F.; Dietmaier, W., Smoking
and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J
Pathol 2006, 210 (2), 192-204.
81.  Gümüş,  Z.  H.;  Du,  B.;  Kacker,  A.;  Boyle,  J.  O.;  Bocker,  J.  M.;  Mukherjee,  P.;
Subbaramaiah, K.; Dannenberg, A. J.; Weinstein, H., Effects of tobacco smoke on gene expression
and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res 2008, 1 (2), 100-
11.
82. Penning, T. M.; Lerman, C., Genomics of smoking exposure and cessation: lessons for
cancer prevention and treatment. Cancer Prev Res 2008, 1 (2).
83. Nagaraj, N. S.; Beckers, S.; Mensah, J. K.; Waigel, S.; Vigneswaran, N.; Zacharias, W.,
Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer
cells. Toxicology letters 2006, 165 (2), 182-194.
84. Jin, Y.; Penning, T. M., Aldo-keto reductases and bioactivation/detoxication. Annu Rev
Pharmacol Toxicol 2007, 47, 263-292.
85. Ohta, T.; Iijima, K.; Miyamoto, M.; Nakahara, I.; Tanaka, H.; Ohtsuji, M.; Suzuki, T.;
Kobayashi, A.; Yokota, J.; Sakiyama, T.; Shibata, T.; Yamamoto, M.; Hirohashi, S., Loss of Keap1
Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth. Cancer Research
2008, 68 (5), 1303-1309.
86. Singh, A.; Misra, V.; Thimmulappa, R. K.; Lee, H.; Ames, S.; Hoque, M. O.; Herman, J.
G.; Baylin, S. B.; Sidransky, D.; Gabrielson, E.; Brock, M. V.; Biswal, S., Dysfunctional KEAP1–
NRF2 Interaction in Non-Small-Cell Lung Cancer. PLoS Medicine 2006, 3 (10), e420.
87.  Stiborová,  M.;  Dracínská,  H.;  Mizerovská,  J.;  Frei,  E.;  Schmeiser,  H.  H.;  Hudecek,  J.;
Hodek, P.; Phillips, D. H.; Arlt, V. M., The environmental pollutant and carcinogen 3-
nitrobenzanthrone induces cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase in rat
lung and kidney, thereby enhancing its own genotoxicity. Toxicology 2008, 247 (1), 11-22.
88. Hajos, A. K.; Winston, G. W., Dinitropyrene nitroreductase activity of purified NAD(P)H-
quinone oxidoreductase: role in rat liver cytosol and induction by Aroclor-1254 pretreatment.
Carcinogenesis 1991, 12 (4), 697-702.
89. Agyeman, A. S.; Chaerkady, R.; Shaw, P. G.; Davidson, N. E.; Visvanathan, K.; Pandey,
A.; Kensler, T. W., Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-
treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat
2012, 132 (1), 175-87.
90.  Ciaccio,  P.  J.;  Shen,  H.;  Jaiswal,  A.  K.;  Lyttle,  M.  H.;  Tew,  K.  D.,  Modulation  of
detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors.
Mol Pharmacol 1995, 48 (4), 639-47.
91. Ciaccio, P. J.; Jaiswal, A. K.; Tew, K. D., Regulation of human dihydrodiol dehydrogenase
by Michael acceptor xenobiotics. J Biol Chem 1994, 269 (22), 15558-62.
92. Lou, H.; Du, S.; Ji, Q.; Stolz, A., Induction of AKR1C2 by phase II inducers: identification
of a distal consensus antioxidant response element regulated by NRF2. Mol Pharmacol 2006, 69
(5), 1662-72.
93. Burczynski, M. E.; Lin, H. K.; Penning, T. M., Isoform-specific induction of a human aldo-
keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress:
implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol
dehydrogenase. Cancer Res 1999, 59 (3), 607-614.
94. Burczynski, M. E., Harvey, R.G., and Penning, T.M., Expression and characterization of
four recombinant human dihydrodiol dehydrogenase isoforms: Oxidation of trans-7,8-dihydroxy-
7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione.
Biochemistry 1998, 37, 6781-6790.
95. Palackal, N. T., Burczynski, M.E., Harvey, R.G. and Penning, T.M., The ubiquitous
aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones:
Potential role in polycyclic aromatic hydrocarbon activation. Biochemistry 2001, 40, 10901-
10910.
96. Palackal NT, L. S., Harvey RG, Blair IA, Penning TM., Activation of polycyclic aromatic
hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C)
enzymes and their functional overexpression in human lung carcinoma (A549) cells. J. Biol. Chem.
2002, 24, 24799-808.
97. Smithgall, T. E., Harvey, R.G. and Penning, T.M., Regio- and stereospecificity of
homogeneous 3a-hydroxysteroid-dihydrodiol dehydrogenase for trans-dihydrodiol metabolites of
polycyclic aromatic hydrocarbons. J. Biol. Chem. 1986, 261, 6184-6191.
98. Smithgall, T. E., Harvey, R.G. and Penning, T.M., Spectroscopic identification of ortho-
quinones as the products of polycyclic aromatic trans-dihydrodiol oxidation catalyzed by
dihydrodiol dehydrogenase. A potential route of proximate carcinogen metabolism. J. Biol. Chem.
1988, 263, 1814-1820.
